Authors

Amishi Y. Shah, MD, MD Anderson Cancer Center

Latest:

Incorporating Treatment Advances Into mRCC Management

Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.

Sajid A Khan MD, FACS, FSSO

Latest:

Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer Surgery

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

Sophie Paczesny, MD, PhD

Latest:

The Evolving Field of GVHD Treatment

Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.

Manojkumar Bupathi, MD, MS

Latest:

Dr Bupathi on Updates in the Second-Line Management of Advanced RCC

Manojkumar Bupathi, MD, MS, discusses updates in the second-line management of metastatic renal cell carcinoma and anticipated research in this space.

Maria E. Cabanillas, MD, MD Anderson Cancer Center

Latest:

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

Bradley J. Monk, MD, FACOG, FACS

Latest:

Future Outlook of Advanced Ovarian Cancer Treatment

Comprehensive insights on unmet needs, ongoing research, and the future of advanced ovarian cancer treatment.

Melinda L. Telli, MD

Latest:

Unmet Needs and Future Direction in HER2+ Breast Cancer

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Marina Frimer, MD, FACOG, FACS

Latest:

Dr. Frimer on the Exploration of Maintenance with Niraparib in Uterine Serous Carcinoma

Marina Frimer, MD, FACOG, FACS, discusses the exploration of maintenance with niraparib in a phase 2 trial in patients with advanced or platinum-sensitive recurrent uterine serious carcinoma

Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

Latest:

Bright Future in Advanced Urothelial Cancer

Ian Krop, MD, PhD

Latest:

Unmet Needs and Future Direction in HER2+ Breast Cancer

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Horacio J. Asbun, MD

Latest:

Mapping Progress in Pancreatic Cancer Surgery: Leveraging New Technology

In this last episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, explain how augmented reality or artificial intelligence may be utilized to improve outcomes for patients with pancreatic cancer who are undergoing surgical procedures.

Amanda Nizam, MD

Latest:

Dr Nizam on Enfortumab Vedotin After Maintenance Avelumab in Urothelial Cancer

Amanda Nizam, MD, discusses findings from the UNITE study of enfortumab vedotin after maintenance avelumab in patients with advanced urothelial carcinoma.

Michael Feigin, PhD

Latest:

Dr Feigin on the Effect of Benzodiazepines on Survival Outcomes in Pancreatic Cancer

Michael Feigin, PhD, discusses data from a retrospective study investigating the association between benzodiazepines and survival outcomes in patients with pancreatic cancer.

Jacqueline Aredo, MD, MS

Latest:

Dr Aredo on the Molecular Distribution of Screening-Eligible Patients With NSCLC

Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.

Steven Lee Chang, MD

Latest:

Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Katharine A. Price, MD

Latest:

Dr Price on the Potential Role for HPV-Targeted Immunotherapy Vaccines in HPV+ HNSCC

Katharine A. Price, MD, discusses the potential role for injectable HPV-targeted immunotherapy vaccines in HPV16-positive head and neck squamous cell carcinoma.

Omar Abughanimeh, MD

Latest:

Dr Abughanimeh on the Evolution of Targeted Therapy in EGFR+ NSCLC

Omar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.

Shahzad Raza, MD

Latest:

Prevalence of Eye Toxicities in Patients With Cancer Is Much Higher Than Previously Known

In the real-world setting, cases of ocular adverse effects have emerged with greater frequency both in new and established therapies than has been previously observed in many clinical trials.

Marco Davila, MD, PhD

Latest:

Gene and Cell Therapy: Shaping the Future of Medicine

Marco Davila, MD, PhD, discusses how to shape the future of medicine with gene and cell therapy.

Latest:

How Genomic Testing and Targeted Therapies Are Shifting the Mindset for Treating Acute Myeloid Leukemia

Questions and answers with Dr. Eunice Wang, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, an unpaid Astellas consultant

Peter G. Miller, MD, PhD

Latest:

Dr. Miller on the Characteristics of Clonal Hematopoiesis

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

Kami J. Maddocks, MD

Latest:

Future Directions in the Treatment of Mantle Cell Lymphoma

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.

Hyunseok Kang, MD

Latest:

Exploring Real-World Evidence Presented at ATA 2023

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Muhammad B. Abid, MD, MRCP

Latest:

Dr. Abid on Adaptive Lymphodepletion in CAR T-Cell Recipients in R/R B-Cell NHL

Muhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.

Myung-Ju Ahn, MD